NVAX news

Latest 10 stories · newest Oct 29, 2026

NVAX
Novavax Earns $125M from Sanofi Phase 3 Influenza Vaccine Trial

Novavax received a $125M milestone payment as Sanofi initiated a Phase 3, combination influenza-COVID-19 vaccine trial in Europe. Future collaboration milestones include an additional $300M upon U.S. launch.

M&A Oct 29, 2026 sentiment +0.30 SEC filing ↗
NVAX
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
News Oct 19, 2026 sentiment -0.30 Source: benzinga.com ↗
NVAX
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
News Oct 12, 2026 sentiment -0.20 Source: benzinga.com ↗
NVAX
Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York Times
News Oct 9, 2026 sentiment 0.00 Source: benzinga.com ↗
NVAX
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
Media Oct 9, 2026 sentiment +0.20 Source: benzinga.com ↗
NVAX
'Russia Denies Report of Second Case of Illness in Siberia' - Bloomberg
News Oct 8, 2026 sentiment 0.00 Source: benzinga.com ↗
NVAX
Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety
Markets Oct 6, 2026 sentiment +0.20 Source: benzinga.com ↗
NVAX
Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
Markets Aug 20, 2026 sentiment 0.00 Source: benzinga.com ↗
NVAX
Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All Children
News Aug 10, 2026 sentiment 0.00 Source: benzinga.com ↗
NVAX
Novavax reports Q2 revenue and updates 2026 guidance

Novavax reported $57M revenue and upwardly revised its 2026 revenue guidance driven by potential earnings from a Sanofi combination trial and existing collaborations. Sentiment reflects a shift toward positive operational visibility.

Earnings|Guidance Aug 6, 2026 sentiment +0.30 SEC filing ↗
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same NVAX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/NVAX/newsSTART FREE